AIR Recon DL, a deep learning-based image reconstruction software, will now be available with 3D sequences as well as PROPELLER motion-insensitive sequences on magnetic resonance imaging (MRI) scanners from GE Healthcare.
The Food and Drug Administration (FDA) has expanded the 510(k) clearance for GE Healthcare’s AIR Recon DL, enabling radiologists to apply the adjunctive deep learning-based technology to 3D sequences as well as the company’s PROPELLER motion-insensitive sequences for magnetic resonance imaging (MRI).
Noting enhanced image sharpness and an improved signal-to-noise (SNR) ratio, GE Healthcare said the compatibility of AIR Recon DL with 3D MRI imaging reduces the need for repeat 2D scans and may facilitate quick imaging results.
For pediatric, neurodegenerative, geriatric, and claustrophobic patients who may have trouble staying still for MRI exams, GE Healthcare noted the combination of PROPELLER sequencing and AIR Recon DL should lead to shorter exam times, faster patient throughput and an enhanced patient experience.
“By expanding AIR Recon DL to 3D and PROPELLER, GE Healthcare has closed the gaps in our ability to provide improved image quality and patient experience to all our patients across exam types, particularly for brain imaging where we rely heavily on 3D sequences and musculoskeletal imaging where PROPELLER is important for reducing image quality variability and eliminating repeat sequences due to motion,” noted Tiron Pechet, MD, an assistant professor of radiology at the University of Massachusettes Medical School and an assistant medical director with Shields Health Care Group.
In addition to being available on the GE Healthcare’s new MRI scanners, the expanded applications of AIR Recon DL to 3D and PROPELLER sequences will be available as upgrades for previously installed 1.5T and 3.0T MRI systems from the company, according to GE Healthcare.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.